Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity RatioInvested CapitalReturn on AssetsReturn on Capital Employed

Cardiol Therapeutics (CRDL) Debt to Equity (2021 - 2025)

Cardiol Therapeutics filings provide 2 years of Debt to Equity readings, the most recent being $0.01 for Q4 2022.

  • On a quarterly basis, Debt to Equity fell 90.79% to $0.01 in Q4 2022 year-over-year; TTM through Dec 2022 was $0.01, a 90.79% decrease, with the full-year FY2022 number at $0.01, down 90.79% from a year prior.
  • Debt to Equity hit $0.01 in Q4 2022 for Cardiol Therapeutics, down from $0.09 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.09 in Q4 2021 to a low of $0.01 in Q4 2022.